GSK (NYSE:GSK – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.
Insider and Institutional Ownership
15.7% of GSK shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for GSK and Evolus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GSK | 2 | 7 | 0 | 1 | 2.00 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Valuation and Earnings
This table compares GSK and Evolus”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GSK | $33.20 billion | 2.93 | $7.54 billion | $3.20 | 15.04 |
| Evolus | $316.49 million | 1.64 | -$51.64 million | ($0.52) | -15.08 |
GSK has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
GSK has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.
Profitability
This table compares GSK and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GSK | 14.56% | 43.23% | 11.60% |
| Evolus | -10.85% | N/A | -13.00% |
Summary
GSK beats Evolus on 10 of the 15 factors compared between the two stocks.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
